Compare Wahed FTSE USA Shariah ETF (HLAL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Neurocrine Biosciences Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $71.3, while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). Which is the better fit depends on your goals.
| HLAL | NBIX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $180.55 |
52-Week Low | $54.05 | $123.10 |
Market Cap | — | $17.40B |
Enterprise Value | — | $16.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
